Atherosclerotic plaque inflammation varies between vascular sites and correlates with response to inhibition of lipoprotein-associated phospholipase A2.

30 The Lp‐PLA2 inhibitor rilapladib clinically showed no significant effect of treatment on FDG‐PET uptake at the carotid and ascending aorta sites, 31 and most recently, in a randomized clinical trial of darapladib in stable coronary heart disease, there was a nominally significant reduction in the risk of 2 secondary composite end points of major coronary events and total coronary events, while darapladib had no effect on stroke. 8 These translational findings are relevant to several aspects of atherosclerosis research.

also in 7,732 other papers